Loading...
XNASMLYS
Market cap491mUSD
Jan 10, Last price  
9.87USD
1D
-11.88%
1Q
-27.21%
IPO
-46.76%
Name

Mineralys Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:MLYS chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-72m
L+141.28%
-3,426,000-19,408,000-29,799,000-71,898,000
CFO
-81m
L+177.79%
-2,463,000-14,559,000-29,221,000-81,173,000
Earnings
Mar 17, 2025

Profile

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
URL
https://mineralystx.com/
IPO date
Feb 10, 2023
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
84,657
31,479
Unusual Expense (Income)
NOPBT
(84,657)
(31,479)
NOPBT Margin
Operating Taxes
(1,904)
Tax Rate
NOPAT
(84,657)
(29,575)
Net income
(71,898)
141.28%
(29,799)
53.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
202,990
126,390
BB yield
-65.22%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(239,049)
(110,110)
Cash flow
Cash from operating activities
(81,173)
(29,221)
CAPEX
Cash from investing activities
(160,472)
(21,759)
Cash from financing activities
203,248
128,019
FCF
(86,711)
(29,575)
Balance
Cash
236,567
110,110
Long term investments
2,482
Excess cash
239,049
110,110
Stockholders' equity
(124,704)
(52,809)
Invested Capital
365,858
159,184
ROIC
ROCE
EV
Common stock shares outstanding
36,188
40,857
Price
8.60
 
Market cap
311,219
 
EV
72,170
EBITDA
(84,657)
(31,479)
EV/EBITDA
Interest
1,676
Interest/NOPBT